» Articles » PMID: 9002493

The Costs of Adverse Drug Events in Hospitalized Patients. Adverse Drug Events Prevention Study Group

Overview
Journal JAMA
Specialty General Medicine
Date 1997 Jan 22
PMID 9002493
Citations 425
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the additional resource utilization associated with an adverse drug event (ADE).

Design: Nested case-control study within a prospective cohort study.

Participants: The cohort included 4108 admissions to a stratified random sample of 11 medical and surgical units in 2 tertiary-care hospitals over a 6-month period. Cases were patients with an ADE, and the control for each case was the patient on the same unit as the case with the most similar pre-event length of stay.

Main Outcome Measures: Postevent length of stay and total costs.

Methods: Incidents were detected by self-report stimulated by nurses and pharmacists and by daily chart review, and were classified as to whether they represented ADEs. Information on length of stay and charges was obtained from billing data, and costs were estimated by multiplying components of charges times hospital-specific ratios of costs to charges.

Results: During the study period, there were 247 ADEs among 207 admissions. After outliers and multiple episodes were excluded, there were 190 ADEs, of which 60 were preventable. In paired regression analyses adjusting for multiple factors, including severity, comorbidity, and case mix, the additional length of stay associated with an ADE was 2.2 days (P=.04), and the increase in cost associated with an ADE was $3244 (P=.04). For preventable ADEs, the increases were 4.6 days in length of stay (P=.03) and $5857 in total cost (P=.07). After adjusting for our sampling strategy, the estimated postevent costs attributable to an ADE were $2595 for all ADEs and $4685 for preventable ADEs. Based on these costs and data about the incidence of ADEs, we estimate that the annual costs attributable to all ADEs and preventable ADEs for a 700-bed teaching hospital are $5.6 million and $2.8 million, respectively.

Conclusions: The substantial costs of ADEs to hospitals justify investment in efforts to prevent these events. Moreover, these estimates are conservative because they do not include the costs of injuries to patients or malpractice costs.

Citing Articles

Reporting on knowledge, attitudes, and behaviours of pharmacists regarding the active offer of French language health services in Ontario: A quantitative survey study.

Timony P, Leone A, Caron C, Giguere P, Thabet P, Gauthier A Can Pharm J (Ott). 2025; :17151635241308874.

PMID: 39885954 PMC: 11775929. DOI: 10.1177/17151635241308874.


Economic impact and clinical benefits of clinical pharmacy interventions: A six-year multi-center study using an innovative medication management tool.

Alsetohy W, El-Fass K, El Hadidi S, Zaitoun M, Badary O, Ali K PLoS One. 2025; 20(1):e0311707.

PMID: 39823444 PMC: 11741631. DOI: 10.1371/journal.pone.0311707.


Pharmacy Integrated Transitions (PIT) trial: a protocol for a pragmatic cluster-randomised crossover trial.

Hantouli M, Monsell S, Davidson G, Chaing J, Comstock B, Dervish A BMJ Open. 2024; 14(12):e088786.

PMID: 39740951 PMC: 11749757. DOI: 10.1136/bmjopen-2024-088786.


Adverse drug reactions and its associated factors among geriatric hospitalized patients at selected comprehensive specialized hospitals of the Amhara Region, Ethiopia: a multicenter prospective cohort study.

Dagnew S, Moges T, Ayele T, Wondm S, Yazie T, Dagnew F BMC Geriatr. 2024; 24(1):955.

PMID: 39550566 PMC: 11568537. DOI: 10.1186/s12877-024-05515-y.


Medication Errors in Saudi Arabian Hospital Settings: A Systematic Review.

Tobaiqy M, MacLure K Medicina (Kaunas). 2024; 60(9).

PMID: 39336452 PMC: 11433733. DOI: 10.3390/medicina60091411.